1.47
Schlusskurs vom Vortag:
$1.42
Offen:
$1.43
24-Stunden-Volumen:
250.58K
Relative Volume:
0.35
Marktkapitalisierung:
$60.63M
Einnahmen:
$68.68M
Nettoeinkommen (Verlust:
$-60.84M
KGV:
-0.9188
EPS:
-1.6
Netto-Cashflow:
$-38.42M
1W Leistung:
-2.00%
1M Leistung:
-24.62%
6M Leistung:
-4.55%
1J Leistung:
-80.08%
Pulmonx Corp Stock (LUNG) Company Profile
Firmenname
Pulmonx Corp
Sektor
Branche
Telefon
650-364-0400
Adresse
700 CHESAPEAKE DRIVE, REDWOOD CITY
Compare LUNG vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
|
LUNG
Pulmonx Corp
|
1.47 | 58.57M | 68.68M | -60.84M | -38.42M | -1.60 |
|
ABT
Abbott Laboratories
|
112.68 | 193.83B | 44.33B | 6.48B | 6.92B | 3.7033 |
|
SYK
Stryker Corp
|
366.05 | 140.01B | 25.12B | 3.25B | 4.28B | 8.3984 |
|
MDT
Medtronic Plc
|
99.49 | 129.33B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
BSX
Boston Scientific Corp
|
74.73 | 109.92B | 20.08B | 2.89B | 3.82B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
75.87 | 44.36B | 6.07B | 1.06B | 799.60M | 1.8527 |
Pulmonx Corp Stock (LUNG) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-31 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2025-03-10 | Eingeleitet | D. Boral Capital | Buy |
| 2024-12-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-06-04 | Eingeleitet | Lake Street | Buy |
| 2024-02-23 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-09-05 | Eingeleitet | Craig Hallum | Buy |
| 2023-02-27 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-01-03 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-12-12 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-07-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-03-02 | Fortgesetzt | BofA Securities | Neutral |
| 2021-12-08 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-04-01 | Eingeleitet | Citigroup | Buy |
| 2021-03-25 | Eingeleitet | Piper Sandler | Neutral |
| 2021-03-10 | Hochstufung | BofA Securities | Neutral → Buy |
| 2021-01-04 | Herabstufung | BofA Securities | Buy → Neutral |
| 2020-10-26 | Eingeleitet | BofA Securities | Buy |
| 2020-10-26 | Eingeleitet | Canaccord Genuity | Buy |
| 2020-10-26 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2020-10-26 | Eingeleitet | Stifel | Buy |
| 2020-10-26 | Eingeleitet | Wells Fargo | Equal Weight |
Alle ansehen
Pulmonx Corp Aktie (LUNG) Neueste Nachrichten
Pulmonx Stock Under Pressure: Can A Niche Lung-Health Innovator Breathe New Life Into Its Shares? - AD HOC NEWS
Will Pulmonx Corporation stock beat EPS estimatesWeekly Risk Summary & Stock Portfolio Risk Control - mfd.ru
Pulmonx (LUNG) Expected to Announce Earnings on Wednesday - Defense World
Merger Talk: Is Pulmonx Corporation a good ESG investment2025 Key Highlights & Free Community Consensus Stock Picks - baoquankhu1.vn
Pulmonx Aktie: Zahlen im Fokus - Börse Global
Pulmonx Q4 2025 Results: A Litmus Test for New Leadership - AD HOC NEWS
Sentiment Watch: Is Pulmonx Corporation a turnaround story2025 Technical Patterns & Weekly Top Gainers Alerts - baoquankhu1.vn
US Market Wrap: Can Cabaletta Bio Inc disrupt its industryJuly 2025 Outlook & Reliable Entry Point Alerts - baoquankhu1.vn
Analyzing Pulmonx (NASDAQ:LUNG) and Privia Health Group (NASDAQ:PRVA) - Defense World
Pulmonx Corporation (NASDAQ:LUNG) Given Average Recommendation of "Hold" by Analysts - MarketBeat
Aug Rallies: How Pulmonx Corporation stock compares to growth peersJuly 2025 Gainers & Reliable Volume Spike Alerts - Bộ Nội Vụ
Why The Pulmonx LUNG Narrative Is Shifting After Target Cut And Leadership Return - Yahoo Finance
Is Pulmonx Corporation stock vulnerable to regulatory risks2025 Price Targets & Weekly High Potential Alerts - Улправда
How Pulmonx Corporation stock valuations compare to rivalsTrade Performance Summary & AI Driven Stock Price Forecasts - Улправда
Pulmonx Corporation (NASDAQ:LUNG) Given Consensus Rating of "Hold" by Brokerages - MarketBeat
Pulmonx Corporation (NASDAQ:LUNG) Given Consensus Rating of “Hold” by Brokerages - Defense World
How Leadership Changes And Analyst Revisions Are Shaping Pulmonx's Valuation Story - Yahoo Finance
Pulmonx (NASDAQ:LUNG) Trading Up 2.5%Here's What Happened - MarketBeat
EBITDA per share of Pulmonx Corp. – GETTEX:4NI - TradingView — Track All Markets
What technical charts say about Pulmonx Corporation stockWeekly Stock Summary & AI Enhanced Trade Execution Alerts - Улправда
Why Pulmonx Corporation stock is in analyst buy zoneJuly 2025 PreEarnings & AI Driven Stock Reports - Улправда
Can Pulmonx Corporation stock hit analyst price targetsDay Trade & Reliable Price Action Trade Plans - Улправда
How strong is Pulmonx Corporation stock revenue growthQuarterly Trade Report & Short-Term High Return Ideas - Улправда
Can Pulmonx Corporation stock resist sector downturnsJuly 2025 Drop Watch & Breakout Confirmation Alerts - Улправда
Will Pulmonx Corporation stock deliver better than expected guidanceJuly 2025 Closing Moves & Community Trade Idea Sharing - Улправда
How Pulmonx Corporation stock performs in interest rate cyclesJuly 2025 Patterns & High Conviction Investment Ideas - Улправда
Will Pulmonx Corporation stock continue upward momentumJuly 2025 Opening Moves & Stepwise Trade Signal Guides - Улправда
Pulmonx Navigates Leadership Shift Amidst Mixed Financial Results - AD HOC NEWS
What New Catalysts Are Shifting the Pulmonx Story for Investors - Yahoo Finance
Comparing Careview Communications (OTCMKTS:CRVW) and Pulmonx (NASDAQ:LUNG) - Defense World
Insider Selling: Daniel Florin Sells Shares of Pulmonx Corp (LUN - GuruFocus
Pulmonx Corp Director Daniel P Florin Sells 23,321 Shares - TradingView — Track All Markets
Check out these key findings about Pulmonx Corp (LUNG) - setenews.com
Dir Florin Files To Sell 23,321 Of Pulmonx Corp [LUNG] - TradingView — Track All Markets
Pulmonx (LUNG) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Improved Revenues Required Before Pulmonx Corporation (NASDAQ:LUNG) Stock's 26% Jump Looks Justified - simplywall.st
Insider Selling: Pulmonx (NASDAQ:LUNG) General Counsel Sells 10,278 Shares of Stock - MarketBeat
Pulmonx (NASDAQ:LUNG) CEO Glendon French III Sells 8,805 Shares - MarketBeat
Pulmonx CEO French sells $13.8k in LUNG stock By Investing.com - Investing.com Australia
Pulmonx CEO French sells $13.8k in LUNG stock - Investing.com India
Pulmonx Corp General Counsel Sells Shares to Cover Tax Obligations - TradingView
LUNG FinancialsIncome Statement - Quiver Quantitative
Pulmonx Corporation Grants 1,625,000 Equity Awards as Part of 2025 Inducement Plan - Quiver Quantitative
Pulmonx (Nasdaq: LUNG) issues 1,625,000-share inducement grants, incl. 1.6M RSUs/PSUs - Stock Titan
Pulmonx Corporation (NASDAQ:LUNG) Given Average Recommendation of “Hold” by Brokerages - Defense World
Pulmonx Corporation (NASDAQ:LUNG) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
Check Out Pulmonx Corp (LUNG)’s Trade Data Rather Than the Analysts’ Views - Setenews
Comparing Pulmonx (NASDAQ:LUNG) and Standard BioTools (NASDAQ:LAB) - Defense World
[S-3/A] Pulmonx Corp Amended Shelf Registration Statement | LUNG SEC FilingForm S-3/A - Stock Titan
[S-8] Pulmonx Corp Employee Benefit Plan Registration | LUNG SEC FilingForm S-8 - Stock Titan
Holdings of Pulmonx Corp (LUNG) are aligned with the stars - setenews.com
Finanzdaten der Pulmonx Corp-Aktie (LUNG)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):